Similar articles

• Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin.

  Cheng H, Rogers JD, Sweany AE, Dobrinska MR, Stein EA, Tate AC, Amin RD, Quan H. Cheng H, et al. Pharm Res. 1992 Dec;9(12):1629-33. doi: 10.1023/a:1015828811865. Pharm Res. 1992. PMID: 1488408
• Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.

  Cohen LH, van Vliet A, Roodenburg L, Jansen LM, Griffioen M. Cohen LH, et al. Biochem Pharmacol. 1993 Jun 9;45(11):2203-8. doi: 10.1016/0006-2952(93)90190-8. Biochem Pharmacol. 1993. PMID: 8517861
• Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells.

  Morikawa S, Umetani M, Nakagawa S, Yamazaki H, Suganami H, Inoue K, Kitahara M, Hamakubo T, Kodama T, Saito Y. Morikawa S, et al. J Atheroscler Thromb. 2000;7(3):138-44. doi: 10.5551/jat1994.7.138. J Atheroscler Thromb. 2000. PMID: 11480454
• Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors.

  Sirtori CR. Sirtori CR. Pharmacol Ther. 1993 Dec;60(3):431-59. doi: 10.1016/0163-7258(93)90031-8. Pharmacol Ther. 1993. PMID: 8073070 Review.
• Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.

  Hsu I, Spinler SA, Johnson NE. Hsu I, et al. Ann Pharmacother. 1995 Jul-Aug;29(7-8):743-59. doi: 10.1177/106002809502907-818. Ann Pharmacother. 1995. PMID: 8520093 Review.